Drug Profile
OP 11
Alternative Names: OP-11; ZSTK-474Latest Information Update: 03 Jan 2023
Price :
$50
*
At a glance
- Originator Zenyaku Kogyo
- Developer Ohara Pharmaceutical; Zenyaku Kogyo
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Soft tissue sarcoma
- Discontinued Inflammation; Solid tumours
Most Recent Events
- 03 Jan 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease) in Japan (PO)
- 03 Jan 2023 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (PO)
- 03 Jan 2023 Discontinued - Preclinical for Inflammation in Japan (unspecified route)